BioMarin Pharmaceuticals BMRN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $766.21M-12.4% | $874.57M+12.7% | $776.13M-6.0% | $825.41M+10.8% | $745.15M-0.3% | ||
| $195M-29.3% | $275.71M+96.8% | $140.09M-6.7% | $150.09M-1.0% | $151.56M+11.3% | ||
| $571.21M-4.6% | $598.86M-5.8% | $636.05M-5.8% | $675.32M+13.8% | $593.59M-2.9% | ||
| 74.6%+6.1pp | 68.5%-13.5pp | 82%+0.1pp | 81.8%+2.2pp | 79.7%-2.1pp | ||
| $178.8M-7.1% | $192.41M-53.0% | $409.48M+154% | $161.31M+1.6% | $158.73M-8.5% | ||
| $258.29M-42.1% | $446.21M+66.2% | $268.42M+15.6% | $232.28M+12.7% | $206.12M-22.7% | ||
| $43.46M— | —— | $49.27M+3.6% | $47.53M+26.1% | $37.7M— | ||
| $16.41M-19.7% | $20.44M+10.6% | $18.49M-0.4% | $18.56M-15.9% | $22.07M-6.5% | ||
| $0— | —— | —— | —— | $2.97M— | ||
| $3.96M+286% | $1.03M-79.9% | $5.09M+5.4% | $4.83M+347% | -$1.95M+71.6% | ||
| $636.57M-30.7% | $919.18M+11.7% | $822.83M+50.0% | $548.52M+5.2% | $521.25M-11.0% | ||
| $129.64M— | —— | -$46.69M-117% | $276.89M+23.7% | $223.89M+38.7% | ||
| 16.9%— | —— | -6%-39.6pp | 33.5%+3.5pp | 30%+8.4pp | ||
| $14.96M+438% | $2.78M+7.7% | $2.58M-3.7% | $2.68M-6.4% | $2.86M+11.1% | ||
| $22.56M+17.4% | $19.21M+7.6% | $17.85M-5.2% | $18.83M-1.0% | $19.01M+7.5% | ||
| $5.37M— | —— | —— | $649K-48.8% | $1.27M— | ||
| $141.2M— | $0+100% | -$26.32M-109% | $297.87M+25.1% | $238.09M+40.4% | ||
| $35.68M+83.7% | $19.42M+339% | $4.42M-92.3% | $57.34M+9.4% | $52.4M+17.2% | ||
| $105.53M— | —— | -$30.74M-113% | $240.53M+29.5% | $185.69M+48.6% | ||
| 13.8%— | —— | -4%-33.1pp | 29.1%+4.2pp | 24.9%+8.2pp | ||
| $0.54— | —— | -$0.16-113% | $1.23+29.5% | $0.95+46.2% | ||
| $0.55— | —— | -$0.16-113% | $1.25+28.9% | $0.97+47.0% | ||
| 197.7M+0.1% | 197.4M+2.8% | 192M-2.6% | 197.1M+0.3% | 196.5M-0.1% | ||
| 192.5M+0.4% | 191.8M-0.1% | 192M+0.1% | 191.9M+0.5% | 191M+0.5% | ||
| $455K— | —— | $978K-27.8% | $1.36M-0.5% | $1.36M— | ||
| $43.46M— | —— | $49.27M+3.6% | $47.53M+26.1% | $37.7M— | ||
| $487K— | —— | —— | —— | $485K— | ||
| $279K— | —— | —— | —— | $27K— | ||
| $6.09M+832% | $653K+0.6% | $649K-1.7% | $660K0.0% | $660K0.0% | ||
| $4.48M-7.5% | $4.85M0.0% | $4.85M0.0% | $4.85M0.0% | $4.85M-49.8% | ||
| 13.8M— | —— | 16.8M— | —— | 11.7M— | ||
| $11.2M— | —— | —— | —— | $4.47M+377% | ||
| $4.48M— | —— | —— | —— | $0— | ||
| $1.76B— | —— | $36.29M-78.0% | $165.01M+55.7% | $105.96M— | ||
| -$5M— | —— | —— | -$19.8M-22.2% | -$16.2M— | ||
| $114.76M— | —— | -$20.12M-111% | $176.82M+23.5% | $143.18M— | ||
| $9.22M+1,404% | $613K— | —— | $33.34M+17.3% | $28.43M-32.9% | ||
| $8.8M— | —— | $10.6M0.0% | $10.6M-24.8% | $14.1M— | ||
| $1.41M— | —— | —— | -$3.06M-116% | -$1.42M-157% | ||
| -$6.71M— | —— | -$5.55M— | —— | $10.03M— | ||
| $14.64M-43.7% | $26M+232% | $7.82M-85.0% | $52M+401% | $10.39M-51.0% | ||
| $3.1M— | —— | $116.37M+1,918% | $5.77M+317% | -$2.66M+97.4% | ||
| $7.16M-94.1% | $120.68M— | —— | $98.53M+71.1% | $57.59M— | ||
| -$44.49M-345% | $18.13M-31.1% | $26.33M-45.3% | $48.13M+97.8% | $24.34M-29.0% | ||
| $11.55M+128% | -$41.02M-341% | $17.03M+94.3% | $8.77M+38.5% | $6.33M— | ||
| -$1.48M-125% | $5.89M-69.3% | $19.17M+61.4% | $11.88M+632% | $1.62M-96.1% | ||
| $8.7M— | —— | $16.36M+372% | $3.47M+67.6% | $2.07M-54.3% | ||
| $8.81M— | —— | —— | —— | $1.88M— | ||
| $1.83M— | —— | $0-100% | $1.83M0.0% | $1.83M— | ||
| $813.17M— | $0+100% | -$2.17M+52.9% | -$4.6M+88.1% | -$38.78M— | ||
| $725.53M+1,809% | -$42.45M+87.2% | -$330.96M-2,528% | -$12.59M+55.4% | -$28.24M-137% | ||
| $220.65M+121% | $99.64M-73.0% | $368.69M+99.0% | $185.27M+6.2% | $174.39M-6.1% | ||
| 1— | —— | —— | —— | 1— | ||
| 1— | —— | —— | —— | —— | ||
| -$699K— | —— | $2.65M+104% | -$64.17M-99.2% | -$32.22M— | ||
| $9.24M— | —— | $10.63M+117% | -$63.72M-49.9% | -$42.5M— | ||
| -$1.12M— | —— | $157K+67.0% | $94K-72.8% | $345K— | ||
| $5.37M+98.3% | $2.71M— | $0-100% | $649K-48.8% | $1.27M+106% | ||
| $3.96M+286% | $1.03M-79.9% | $5.09M+5.4% | $4.83M+347% | -$1.95M+71.6% | ||
| -$4.97M— | $0— | —— | —— | $0+100% | ||
| $8.65M— | —— | —— | —— | $0— | ||
| $28.18M+944% | $2.7M+24.1% | $2.18M-82.3% | $12.31M-68.3% | $38.78M+690% | ||
| $25.79M-39.5% | $42.61M-61.6% | $110.83M-2.1% | $113.16M+26.8% | $89.27M+54.2% | ||
| $20.92M-48.6% | $40.72M+43.2% | $28.45M+66.3% | $17.1M+2.0% | $16.77M-14.1% | ||
| $850M— | —— | —— | —— | $0— | ||
| $767.28M+1,674% | $43.25M-56.2% | $98.81M-16.2% | $117.93M+51.6% | $77.8M-49.7% | ||
| -$8.81M— | —— | -$8.14M-1,383% | -$549K-106% | $9.94M— | ||
| $766.21M-12.4% | $874.57M+12.7% | $776.13M-6.0% | $825.41M+10.8% | $745.15M-0.3% | ||
| $43.46M-7.4% | $46.91M-4.8% | $49.27M+3.6% | $47.53M+26.1% | $37.7M-27.4% | ||
| $129.64M+4,567% | $2.78M+106% | -$46.69M-117% | $276.89M+23.7% | $223.89M+38.7% | ||
| $146.05M+529% | $23.22M+182% | -$28.21M-110% | $295.45M+20.1% | $245.96M+32.9% | ||
| $146.05M+529% | $23.22M+182% | -$28.21M-110% | $295.45M+20.1% | $245.96M+32.9% | ||
| 19.1%+16.4pp | 2.7%+6.3pp | -3.6%-39.4pp | 35.8%+2.8pp | 33%+8.3pp | ||
| $129.64M+4,567% | $2.78M+106% | -$46.69M-117% | $276.89M+23.7% | $223.89M+38.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is BioMarin Pharmaceuticals's revenue?
- BioMarin Pharmaceuticals (BMRN) generated $3.2B in revenue over the trailing twelve months, up 9.9% year over year.
- Is BioMarin Pharmaceuticals profitable?
- BioMarin Pharmaceuticals reported $501.0M in net income over the trailing twelve months, a 16.8% net margin.
- What are BioMarin Pharmaceuticals's profit margins?
- Gross margin is 76.5% and operating margin is 19.9%, with a 16.8% net margin.
- What is BioMarin Pharmaceuticals's earnings per share?
- BioMarin Pharmaceuticals's diluted EPS over the trailing twelve months is $2.56.
- Where does BioMarin Pharmaceuticals's income statement data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
